Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N, Garmann D, Lippert J, Heinig R, Brinker M, Heerspink HJL. Eissing T, et al. Among authors: heinig r. Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30. Diabetes Obes Metab. 2024. PMID: 38037539 Clinical Trial.
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. van den Berg P, et al. Among authors: heinig r. Clin Pharmacokinet. 2022 Mar;61(3):439-450. doi: 10.1007/s40262-021-01082-2. Epub 2021 Nov 13. Clin Pharmacokinet. 2022. PMID: 34773606 Free PMC article. Clinical Trial.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Among authors: heinig r. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.
Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Heinig R, et al. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):715-727. doi: 10.1007/s13318-018-0483-9. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29779093 Clinical Trial.
63 results